Don't have access to the rest of the article, but I can't forget this little line from it ever since I read it.

From what I can remember, it was based on some comments made in that quarterly conference call with analysts.

In fact, the outbreak may even lend them a hand in finding clinical-stage assets for the pipeline — if only the biotech execs and boards they approach fully understand the position they’re in.

https://endpts.com/full-steam-ahead-pfizer-goes-bargain-hunting-in-an-age-of-coronavirus-with-a-special-focus-on-cancer-and-rare-diseases/

On a positive note, I noticed yesterday that Pfizer has Steglatro in its arsenal.

Add that to the Zenith-Pfizer equation, and it gets even more interesting.

https://diatribe.org/fda-approves-new-once-daily-pill-type-2-diabetes-steglatro